Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. ACN

Go back to Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) Delayed: 56.50 +0.60 (1.07%)
Previous Close $55.90    52 Week High $108.96 
Open $55.80    52 Week Low $62.12 
Day High $57.00    P/E N/A 
Day Low $55.74    EPS $-1.27 
Volume 1,987,924       

Medivation, Inc. (NASDAQ: MDVN) Delayed: 81.44 --0 (-0%)
Previous Close $81.44    52 Week High $81.48 
Open $3852.47    52 Week Low $26.41 
Day High $81.44    P/E N/A 
Day Low $81.44    EPS $-1.03 
Volume 13,593       

BANCO SANTANDER S.A. (NYSE: SAN) Delayed: 13.60 -0.11 (0.8%)
Previous Close $13.71    52 Week High $5.58 
Open $13.51    52 Week Low $3.60 
Day High $13.62    P/E N/A 
Day Low $13.48    EPS $0.00 
Volume 7,047,778       

SANOFI (NASDAQ: SNY) Delayed: 41.60 -0.18 (0.43%)
Previous Close $41.78    52 Week High $44.76 
Open $42.27    52 Week Low $36.81 
Day High $42.47    P/E N/A 
Day Low $41.47    EPS $0.00 
Volume 10,855,605